Zepbound Side Effects: A Comprehensive Safety Guide
Zepbound (tirzepatide) is used with a reduced-calorie diet and activity for adult chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity. This guide separates pooled trial rates from individual experience, explains warning signs and practical symptom support, and links the current U.S. prescribing information. Current Zepbound U.S. Prescribing Information
What Is Zepbound?
Zepbound is the tirzepatide product for adult chronic weight management and, in adults with obesity, moderate-to-severe obstructive sleep apnea. Mounjaro is the same active ingredient under a different product label for type 2 diabetes, so dosing, age groups, and counseling should not be assumed to be interchangeable. Zepbound is a once-weekly subcutaneous injection that starts at 2.5 mg for four weeks, then increases to 5 mg; later increases are in 2.5 mg steps after at least four weeks on the current dose when response and tolerability support them.
The adult maximum is 15 mg, but reaching 15 mg is not mandatory. For Zepbound, labeled weight-management maintenance doses are 5, 10, or 15 mg; for obstructive sleep apnea with obesity, labeled maintenance doses are 10 or 15 mg. The 2.5 mg dose is for initiation, while 7.5 mg and 12.5 mg are escalation strengths rather than listed maintenance doses. See the labeled dosing and indications
Tirzepatide activates GLP-1 and GIP receptors. That mechanism helps explain why gastrointestinal symptoms, appetite changes, and glucose effects are discussed together, but mechanism alone cannot predict an individual's result or side-effect timing. Do not combine Zepbound with another tirzepatide product or a GLP-1 receptor agonist.
Common Side Effects: What to Expect
Gastrointestinal effects are the most frequently reported effects in the pooled adult weight-management studies. The label's rates below are cumulative proportions of participants in specific trial arms, not per-injection probabilities and not a complete prediction for a person starting 2.5 mg. Most nausea, vomiting, and diarrhea events occurred during dose escalation and decreased over time, but the label does not establish a universal day-of-week peak or recovery deadline.
Nausea
Nausea occurred in 8% of placebo participants and in 25%, 29%, and 28% of participants in the pooled 5 mg, 10 mg, and 15 mg arms. It is common during escalation, but a rate from a trial arm cannot tell you when an individual will feel it or how severe it will be. Slow eating, smaller portions, lower-fat foods when helpful, and a symptom diary are reasonable consensus-based options; persistent or severe nausea deserves a clinical review.
Vomiting
Vomiting occurred in 2% of placebo participants and in 8%, 11%, and 13% of the pooled 5 mg, 10 mg, and 15 mg arms. Repeated vomiting can cause volume depletion. Contact the treating team promptly if you cannot keep fluids down, and seek emergency care when dehydration is severe or you develop confusion, fainting, or another emergency symptom.
Diarrhea
Diarrhea occurred in 8% of placebo participants and in 19%, 21%, and 23% of the pooled 5 mg, 10 mg, and 15 mg arms. Sip fluids according to your needs and any kidney or heart-fluid restrictions, and ask for help if diarrhea is persistent or accompanied by dizziness, markedly reduced urination, or inability to maintain intake. There is no universal duration or glass-count that applies to everyone.
Constipation
Constipation occurred in 5% of placebo participants and in 17%, 14%, and 11% of the pooled 5 mg, 10 mg, and 15 mg arms. Gradually increasing fiber as tolerated, drinking enough within any fluid restrictions, and keeping active may help. Constipation accompanied by severe abdominal pain, distension, vomiting, or inability to pass gas needs assessment before adding fiber or laxatives.
Abdominal Pain
Abdominal pain occurred in 5% of placebo participants and in 9%, 9%, and 10% of the pooled 5 mg, 10 mg, and 15 mg arms. Mild discomfort can have several causes, but persistent or severe pain, particularly pain that may radiate to the back or occurs with vomiting, should not be normalized as routine treatment adjustment. Stop Zepbound and seek prompt evaluation for possible pancreatitis.
Other Common Side Effects
Other pooled events in the same label table included dyspepsia at 4% with placebo versus 9%, 9%, and 10% with 5 mg, 10 mg, and 15 mg; injection-site reaction at 2% versus 6%, 8%, and 8%; fatigue at 3% versus 5%, 6%, and 7%; hair loss at 1% versus 5%, 4%, and 5%; and reflux at 2% versus 4%, 4%, and 5%. Hair loss was associated with weight reduction in the label; these figures do not prove inevitable or permanent hair loss. Review the pooled adverse-reaction table
Serious Side Effects and Safety Concerns
Rare or serious symptoms need a different response from ordinary adjustment symptoms. The current label distinguishes one boxed warning from other warnings and precautions. A serious allergy, severe hypoglycemia, severe dehydration, or severe persistent abdominal pain can require emergency care.
Pancreatitis
Pancreatitis is a warning and precaution, not an additional boxed warning. In pooled adult weight-management Study 1 and Study 2, adjudicated pancreatitis occurred in 0.2% of both tirzepatide and placebo participants. That low observed frequency does not eliminate the possibility of a serious event or replace attention to warning symptoms.
Persistent or severe abdominal pain, with or without vomiting and especially pain that may radiate to the back, requires prompt evaluation. Stop Zepbound while seeking that advice. Do not try to manage a concerning pain pattern with hydration, a supplement, or a self-directed dose change.
Thyroid Cancer Warning
The current boxed warning concerns thyroid C-cell tumors. It is based on rodent findings, and the human relevance is unknown. A personal or family history of medullary thyroid carcinoma (MTC) and Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) are formal contraindications.
A new neck lump, persistent hoarseness, trouble swallowing, or trouble breathing warrants prompt clinical review; breathing difficulty is an emergency. Routine calcitonin testing or thyroid ultrasound is not a guarantee of safety, and the label notes that the value of such monitoring is uncertain.
Gallbladder Disease
In pooled adult weight-management trials, gallstones occurred in 1.1% of tirzepatide participants versus 1.0% of placebo participants, cholecystitis in 0.7% versus 0.2%, and cholecystectomy in 0.2% versus 0%. Gallbladder events were associated with weight reduction. Sudden or persistent right-upper-abdominal pain, fever, jaundice, or vomiting warrants clinical evaluation.
Discuss a history of gallstones with the treating team. New symptoms may call for gallbladder testing and treatment; the appropriate plan depends on the findings rather than a particular weekly weight-loss threshold.
Kidney Problems
Acute kidney injury occurred in 0.5% of tirzepatide participants versus 0.2% of placebo participants in the pooled weight trials. Postmarketing cases have often followed gastrointestinal fluid loss, and some required dialysis. Volume-depleting vomiting or diarrhea is therefore a reason for prompt assessment and, when clinically indicated, kidney-function monitoring.
No renal dose adjustment is recommended, including in end-stage renal disease. People with kidney disease or prescribed fluid restrictions still need an individualized hydration and monitoring plan, especially during vomiting or diarrhea.
Hypoglycemia (Low Blood Sugar)
In the type 2 diabetes study, glucose below 54 mg/dL occurred in 4.2% of tirzepatide participants versus 1.3% of placebo participants. Among tirzepatide-treated participants, the rate was 10.3% with a sulfonylurea versus 2.1% without one. Insulin and insulin secretagogues may require a prescriber-directed reduction and closer glucose monitoring.
SGLT2 inhibitors are not equivalent to insulin or sulfonylureas for this interaction, and Zepbound should not be combined with a GLP-1 receptor agonist. Shaking, sweating, confusion, fainting, seizure, or loss of consciousness needs immediate attention; confusion, seizure, or unconsciousness is an emergency.
Diabetic Retinopathy (Eye Problems)
Rapid improvement in blood sugar can be associated with temporary worsening of diabetic retinopathy. If you have existing retinopathy, coordinate monitoring with the prescribing and eye-care teams. New or worsening vision changes need prompt assessment, and outcomes require clinical follow-up.
Suicidal Thoughts or Behaviors
In January 2026, the FDA reported that its comprehensive review found no increased risk of suicidal ideation or behavior with GLP-1 receptor agonists and requested removal of the historical warning from Saxenda, Wegovy, and Zepbound; the Zepbound warning was removed in February 2026. Read the FDA review and findings
Discuss new or worsening depression, suicidal thoughts, or other mood changes with a clinician. Call or text 988 for a suicidal crisis and call 911 or seek immediate emergency help when there is immediate danger.
Side Effects by Dose Level
Zepbound is labeled through six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. The pooled table below has separate trial arms only for placebo, 5 mg, 10 mg, and 15 mg. It cannot generate starting-dose rates for 2.5 mg or rates for the 7.5 mg and 12.5 mg escalation strengths, and its percentages should not be read as a monotonic severity curve.
| Event | Placebo (N=958) | 5 mg (N=630) | 10 mg (N=948) | 15 mg (N=941) |
|---|---|---|---|---|
| Nausea | 8% | 25% | 29% | 28% |
| Vomiting | 2% | 8% | 11% | 13% |
| Diarrhea | 8% | 19% | 21% | 23% |
| Constipation | 5% | 17% | 14% | 11% |
| Abdominal pain | 5% | 9% | 9% | 10% |
The same pooled label data report overall gastrointestinal adverse reactions in 30% of placebo participants versus 56% in each tirzepatide arm; severe gastrointestinal reactions in 1.0% versus 1.7%, 2.5%, and 3.1%; GI-related discontinuation in 0.5% versus 1.9%, 3.3%, and 4.3%; and discontinuation for any adverse reaction in 3.4% versus 4.8%, 6.3%, and 6.7%. Tirzepatide values are ordered 5 mg, 10 mg, then 15 mg. Having a GI symptom, having a severe event, and stopping treatment are different outcomes.
Timeline: When Side Effects Appear and Resolve
Most nausea, vomiting, and diarrhea in the trials occurred during dose escalation and decreased over time. The checkpoints below can help you track progress and prepare for follow-up. Symptom timing varies, especially when the dose changes.
Week 1: Initial Response
- Confirm the product, strength, injection technique, and weekly schedule.
- Notice nausea, vomiting, diarrhea, constipation, abdominal pain, hydration, food intake, and day-to-day function.
- Seek prompt help for persistent vomiting, inability to keep fluids down, severe pain, or another urgent symptom.
Weeks 2-4: Checking Tolerability
- Keep a simple symptom and intake record; individual timing can vary.
- Before an increase, review whether symptoms and nutrition are manageable and whether the indication-specific goal supports a change.
- The labeled starting schedule is 2.5 mg weekly for four weeks, then 5 mg. Contact the prescriber before that step if symptoms remain troublesome. Any later increase requires at least four weeks at the current dose and depends on response and tolerability.
Weeks 5-8: Reassessing After Dose Changes
- A dose change can bring new or stronger symptoms, but the label does not predict a fixed peak or duration.
- Use smaller portions, slow eating, individualized fluids, and other consensus-based measures when helpful.
- Persistent symptoms should prompt a clinician review rather than an unsupervised dose increase, medication, or supplement regimen.
Weeks 9-16: Finding a Tolerated Dose
- Some people remain at a labeled maintenance dose; others need a slower or different clinician-directed plan.
- Review weight or glucose goals, nutrition, activity, function, and adverse effects together.
- Do not use a rate from a pooled trial arm as a personal prediction or a reason to reach 15 mg.
Month 5 and Beyond: Ongoing Follow-Up
- Continue indication- and symptom-based follow-up even if gastrointestinal symptoms have eased.
- Revisit kidney symptoms after fluid loss, glucose medicines, retinopathy, mood, pregnancy plans, and procedural plans as relevant.
- Long-term tolerability varies; there is no universal deadline by which every side effect must disappear.
These checkpoints support a conversation, not a guarantee. New severe symptoms, inability to maintain fluids, severe hypoglycemia, airway symptoms, or persistent severe abdominal pain need urgent assessment regardless of the week.
Evidence-Based Strategies to Manage and Minimize Side Effects
The following practical measures come from multidisciplinary GLP-1 gastrointestinal-adverse-event consensus rather than a Zepbound-specific randomized symptom-treatment trial. Choose measures that fit the person and indication, and ask a clinician or pharmacist before adding medication or supplements. Multidisciplinary GLP-1 GI adverse-event consensus
Dietary Strategies
Eat slowly, use smaller portions, stop when comfortably full, and try lower-fat or bland foods temporarily if those are easier to tolerate. Small frequent meals can help when appetite is low. Sip fluids throughout the day within any prescribed limits. For constipation, increase fiber gradually as tolerated; during diarrhea, temporarily reducing foods that worsen symptoms can help, then restore a balanced pattern as symptoms settle. A dietitian can help maintain adequate nutrition when appetite or intake falls.
Behavioral Strategies
Remain upright after meals when practical, use light activity as tolerated, and keep a food-and-symptom diary to identify personal triggers. Avoid lying down immediately after eating if reflux is a problem. Ginger food or tea may be a comfort option for some people, but it is not a proven Zepbound antiemetic regimen; mint may worsen reflux for some.
Medical Strategies
A clinician may keep you at the current dose longer, change escalation timing, select a better-tolerated labeled maintenance strength, or prescribe short-term symptom treatment. A pharmacist can help check over-the-counter options against your other medicines and conditions. Discuss persistent symptoms before increasing the dose; severe abdominal pain, distension, or vomiting needs assessment before adding fiber or laxatives.
Effectiveness of Management Strategies
These measures are supported by clinical experience and expert consensus, with limited Zepbound-specific trial evidence for individual symptom remedies. Track whether they improve your ability to eat, drink, and carry out normal activities. If symptoms persist, a dose-plan review or targeted treatment may be more useful than repeatedly adding new remedies.
Long-Term Safety Data from SURMOUNT Trials
The SURMOUNT program provides evidence from weight-management trials lasting 72 weeks and, in a selected group, more than three years. Read each result alongside its population and treatment period; the pooled side-effect rates above combine two studies, while the results below describe individual trials.
SURMOUNT-1 (Primary Trial)
- Participants: 2,539 adults with obesity or overweight plus a qualifying complication, without type 2 diabetes.
- Duration: 72 weeks, including a 20-week dose-escalation period.
- Mean weight change: -15.0% with 5 mg, -19.5% with 10 mg, and -20.9% with 15 mg versus -3.1% with placebo.
- Interpretation: These are study averages, not weekly targets, individual forecasts, or a reason to escalate automatically.
Read the SURMOUNT-1 primary abstract
SURMOUNT-2 and SURMOUNT-3: Different Populations
SURMOUNT-2 studied people with type 2 diabetes. SURMOUNT-3 enrolled 579 adults without diabetes after a 12-week intensive lifestyle lead-in that produced at least 5% weight loss; participants were then randomized to maximum-tolerated tirzepatide 10 or 15 mg or placebo for 72 weeks. From that randomization point, mean additional weight change was -18.4% with tirzepatide versus +2.5% with placebo in the treatment-regimen analysis. Those percentages use weight after the lifestyle phase as their starting point.
Read the SURMOUNT-3 primary report
Extension Trial Data
The extension analysis included 1,032 people with obesity and prediabetes from the original 2,539-person trial. Participants received assigned 5, 10, or 15 mg tirzepatide or placebo for 176 weeks and then had 17 weeks off treatment. Mean weight changes at 176 weeks were -12.3%, -18.7%, and -19.7% for 5, 10, and 15 mg versus -1.3% for placebo; diabetes diagnosis occurred in 1.3% of pooled tirzepatide participants versus 13.3% with placebo, and after 17 weeks off treatment the figures were 2.4% versus 13.7%.
No new safety signals were identified. The most common non-COVID adverse events were gastrointestinal, mostly mild or moderate and concentrated in the first 20-week escalation period. This is reassuring longer-term evidence for that population, while rare or longer-latency risks remain harder to assess. The extension covered the prediabetes subgroup, not every original participant, and its diabetes findings are not a separate approved prevention indication.
Read the obesity and prediabetes extension abstract
Key Safety Takeaways from Long-Term Data
- Study duration, population, indication, dose, and endpoint determine what a safety result means.
- Most gastrointestinal events in the label occurred during escalation and decreased over time, but individual timing varies.
- Continuation studies support ongoing follow-up; they do not establish zero risk or guarantee that every person will tolerate long-term treatment.
- Weight or glucose benefit should be reviewed with nutrition, function, symptoms, and other medicines rather than a single percentage.
- Rare warning signs still require prompt assessment even when trial incidence was low.
Who Should NOT Take Zepbound (Contraindications)
Separate formal contraindications from warnings, precautions, and situations that need an individualized plan. The current U.S. label does not make every condition in the lists below an automatic exclusion.
Absolute Contraindications (Do Not Use)
- Personal or family history of medullary thyroid carcinoma (MTC): Do not use Zepbound.
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2): Do not use Zepbound.
- Known serious hypersensitivity to tirzepatide or an excipient: A prior serious allergic reaction is a formal contraindication.
Situations Requiring a Different Treatment Plan
- Severe gastroparesis: Zepbound is not recommended; discuss alternatives with the treating clinician.
- Pregnancy recognized: Discontinue Zepbound and contact the prescriber. Pregnancy planning also warrants an advance discussion rather than reliance on a fixed interval.
- Persistent or severe abdominal symptoms: Stop and seek prompt evaluation for possible pancreatitis or gallbladder disease rather than continuing escalation.
- Significant vomiting or diarrhea: Volume depletion can affect kidney function; obtain individualized assessment and monitoring.
- Anesthesia or deep sedation: Tell the procedural team that you use Zepbound. Rare aspiration reports have occurred despite fasting, and the procedural team decides the preparation and medicine plan; there is no universal self-directed hold interval.
Relative Cautions (Possible Use with Monitoring)
- History of pancreatitis, gallbladder disease, or diabetic retinopathy: Review the risk and monitoring plan rather than assuming a fixed prohibition.
- Insulin or insulin-secretagogue therapy: Hypoglycemia risk may require prescriber-directed dose adjustment.
- Kidney disease or fluid restriction: No automatic renal dose adjustment is recommended, including ESRD, but vomiting and diarrhea need prompt attention.
- New mood symptoms: The historical suicidal-behavior warning was removed after the FDA review, but new suicidal thoughts or severe depression still require care.
- Other gastrointestinal diagnoses: They are not automatically the same as severe gastroparesis; discuss the diagnosis and symptom burden with the prescriber.
Oral hormonal contraceptive users should switch to a nonoral method or add a barrier method for four weeks after initiation and for four weeks after each escalation, as directed by the product information. Discuss pregnancy plans with the prescriber in advance. Review current contraindications and warnings
Zepbound vs Wegovy: Comparative Side Effect Profile
SURMOUNT-5 directly compared maximum-tolerated injected tirzepatide with injected semaglutide, not oral Wegovy and not semaglutide 7.2 mg. It was an open-label 72-week trial in 751 adults with obesity without type 2 diabetes. The randomized population was 751; the safety population was 374 for tirzepatide and 376 for semaglutide. The observed rates below are descriptive and do not establish an overall safety winner or statistical significance for each difference.
| Outcome | Tirzepatide (n=374) | Semaglutide (n=376) |
|---|---|---|
| Nausea | 43.6% | 44.4% |
| Vomiting | 15.0% | 21.3% |
| Diarrhea | 23.5% | 23.4% |
| Constipation | 27.0% | 28.5% |
| Abdominal pain | 6.4% | 6.9% |
| Injection-site reaction | 8.6% | 0.3% |
| Discontinuation due to adverse event | 6.1% | 8.0% |
Both groups had mostly mild or moderate gastrointestinal events, particularly during escalation. Vomiting was reported less often with tirzepatide, while injection-site reactions were reported more often. Mean weight change was -20.2% with tirzepatide versus -13.7% with semaglutide. These results help frame a discussion of benefit and tolerability, but individual experience can differ. SURMOUNT-5 primary abstract and trial-sponsor safety tables
When to Stop Zepbound and Contact Your Doctor
Stop Zepbound and seek urgent help for suspected pancreatitis or a serious allergic reaction. Severe hypoglycemia or dehydration also needs immediate care; the care team should guide the next doses of Zepbound and any other medicines. For non-emergency symptoms, contact the treating team when they persist, worsen, or interfere with food, fluids, or normal activities.
Seek Emergency Care Immediately:
- Stop Zepbound and call 911 for face, tongue, or throat swelling, trouble breathing, fainting, or another sign of a serious allergic reaction.
- Severe or persistent abdominal pain, especially pain that may radiate to the back, with or without vomiting; stop Zepbound while seeking urgent evaluation.
- Call 911 for severe hypoglycemia with confusion, seizure, loss of consciousness, or inability to safely take corrective action.
- Severe dehydration, inability to keep fluids down, fainting, or confusion after vomiting or diarrhea.
- Immediate danger from suicidal thoughts; call 911 or go to the nearest emergency department.
Contact Your Clinician Promptly:
- Persistent nausea, vomiting, diarrhea, constipation, or abdominal pain that is not settling or is limiting food, fluids, or normal activities.
- New or worsening vision changes, especially with diabetes or known retinopathy.
- A new neck lump, persistent hoarseness, or trouble swallowing.
- New depression, suicidal thoughts without immediate danger, or other concerning mood changes; call or text 988 for a suicidal crisis.
- Symptoms of gallbladder disease, reduced urination after fluid loss, or uncertainty about a new medicine interaction.
- An upcoming procedure involving anesthesia or deep sedation; notify the procedural team in advance.
Discuss Stopping Zepbound with Your Doctor:
- You become pregnant: discontinue Zepbound when pregnancy is recognized and contact the prescriber.
- After urgent assessment for suspected pancreatitis or a serious allergic reaction, review the longer-term treatment plan. Do not wait for a routine appointment to stop the medicine or obtain emergency care.
- You develop severe gastroparesis or a clinically significant gallbladder problem and need to review treatment options.
- Side effects remain unacceptable despite individualized support or a clinician-directed change in escalation or maintenance strength.
- Your treatment indication, other medicines, kidney status, glucose control, or pregnancy plans change.
Recommended Monitoring While on Zepbound
Monitoring should follow the indication, symptoms, risk factors, and other medicines; the label does not require a fixed CBC, metabolic panel, or lipid-panel schedule for every person.
- At follow-up: Review treatment benefit, weight or glucose trend when relevant, nutrition, function, gastrointestinal symptoms, and the reason for any dose change.
- With vomiting or diarrhea: Assess volume status and kidney function when clinically indicated, especially during initiation or escalation.
- With diabetes: Review glucose readings and hypoglycemia risk, particularly with insulin or an insulin secretagogue.
- With retinopathy or new vision symptoms: Coordinate timely eye-care assessment.
- For procedures: Tell the anesthesia or deep-sedation team that you use Zepbound. Rare aspiration reports have occurred despite fasting; the procedural team decides preparation and medication instructions.
- For oral hormonal contraception: Use a nonoral method or add a barrier method for four weeks after starting and for four weeks after each escalation, consistent with the product information.
- For mood or thyroid symptoms: New symptoms deserve clinical care; routine calcitonin or ultrasound testing has uncertain value and does not guarantee safety.
Frequently Asked Questions
Gastrointestinal effects are the most frequently reported effects in the pooled adult weight-management studies. Nausea occurred in 8% of placebo participants versus 25%, 29%, and 28% in the 5 mg, 10 mg, and 15 mg arms; vomiting was 2% versus 8%, 11%, and 13%; diarrhea was 8% versus 19%, 21%, and 23%; constipation was 5% versus 17%, 14%, and 11%; and abdominal pain was 5% versus 9%, 9%, and 10%. These are cumulative participant proportions through up to 72 weeks, not a prediction for one person or one injection.
The label reports that nausea, vomiting, and diarrhea occurred most often during dose escalation and generally decreased over time. It does not establish a universal day-of-week peak, recovery deadline, or fixed week when everyone feels better. Track symptoms around initiation and increases, and contact your clinician for persistent or severe symptoms instead of assuming they are routine adaptation.
A multidisciplinary GLP-1 gastrointestinal-symptom consensus suggests eating slowly, using smaller portions, stopping when comfortably full, choosing lower-fat or bland foods when needed, sipping fluids, remaining upright after meals, keeping a food-and-symptom diary, and using light activity as tolerated. Fluid needs should be individualized, especially with kidney or heart restrictions. Your clinician can adjust escalation timing or choose a better-tolerated labeled maintenance dose; no strategy guarantees prevention.
Nausea can be a common treatment effect, but severity and context matter. Persistent vomiting, inability to keep fluids down, or signs of volume depletion need prompt clinical assessment. Persistent or severe abdominal pain, especially pain that may radiate to the back, can signal pancreatitis and calls for stopping Zepbound and seeking urgent evaluation. Face, tongue, or throat swelling or trouble breathing is an emergency.
Pancreatitis is a warning and precaution, not an additional boxed warning. In pooled adult weight-management Study 1 and Study 2, adjudicated pancreatitis occurred in 0.2% of both tirzepatide and placebo participants. That low observed frequency does not make the risk zero. Stop Zepbound and seek prompt evaluation for persistent or severe abdominal pain, with or without vomiting, particularly if it radiates to the back.
The only boxed warning in the current Zepbound U.S. prescribing information concerns thyroid C-cell tumors. The finding came from rodents, and its relevance to humans is unknown. Do not use Zepbound with a personal or family history of medullary thyroid carcinoma or with MEN 2. A new neck lump, persistent hoarseness, or trouble swallowing warrants prompt clinical review; routine ultrasound or calcitonin testing has uncertain value and does not guarantee safety.
Hypoglycemia risk is most relevant when Zepbound is used with insulin or an insulin secretagogue such as a sulfonylurea. In a type 2 diabetes study, glucose below 54 mg/dL occurred in 4.2% with tirzepatide versus 1.3% with placebo. Among tirzepatide-treated participants, it occurred in 10.3% with a sulfonylurea versus 2.1% without one. Your prescriber may adjust insulin or secretagogue doses and your glucose-monitoring plan. Severe confusion, seizure, or loss of consciousness is an emergency.
The three-year SURMOUNT-1 extension is reassuring: no new safety signals were identified, and the most common non-COVID adverse events were gastrointestinal, mostly mild or moderate and concentrated during dose escalation. It followed 1,032 participants with obesity and prediabetes for 176 weeks plus 17 weeks off treatment, rather than every participant in the original 72-week trial. These findings support longer-term use in appropriately selected patients, while rare and longer-latency risks still need ongoing monitoring.
The formal contraindications are a personal or family history of medullary thyroid carcinoma, MEN 2, and a known serious hypersensitivity to tirzepatide or an excipient. Zepbound is not recommended in severe gastroparesis. If pregnancy is recognized, discontinue Zepbound and contact the prescriber. Other conditions, including pancreatitis history, retinopathy, kidney disease, gallbladder disease, mood symptoms, or diabetes medicines, require an individualized treatment plan rather than an automatic exclusion.
SURMOUNT-5 was an open-label 72-week trial in 751 adults with obesity without type 2 diabetes, comparing maximum-tolerated injected tirzepatide 10 or 15 mg with injected semaglutide 1.7 or 2.4 mg. In the safety population, nausea was 43.6% versus 44.4%, vomiting 15.0% versus 21.3%, diarrhea 23.5% versus 23.4%, constipation 27.0% versus 28.5%, abdominal pain 6.4% versus 6.9%, injection-site reaction 8.6% versus 0.3%, and adverse-event discontinuation 6.1% versus 8.0%. These observed rates do not establish an overall safety winner or predict an individual's tolerance, and they do not compare oral Wegovy or semaglutide 7.2 mg.
Related Resources
- Learn more about tirzepatide (Zepbound and Mounjaro)
- Read our Zepbound vs Wegovy comparison
- Explore compounded tirzepatide as an alternative
- Check out our guide to Zepbound coupons and cost savings
- Learn about Zepbound pricing and insurance coverage